Related Experiment Video
Updated: Apr 6, 2026
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
2.1K
Cardiovascular pharmacotherapy in 2025.
Juan Tamargo1, Stefan Agewall2,3, Giuseppe Ambrosio4,5
1Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, Avenida Ramón y Cajal s/n, Madrid 29040, Spain.
European Heart Journal. Cardiovascular Pharmacotherapy
|April 5, 2026
Summary
Cardiovascular pharmacotherapy advances in 2025 include new drug approvals and expanded uses for existing ones. Research highlights both successful trials and safety concerns, shaping future cardiovascular disease treatment strategies.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Cardiovascular diseases (CVDs) necessitate improved pharmacological treatments.
- Current pharmacotherapy has limitations in efficacy and safety.
Purpose of the Study:
- To review significant 2025 advances in cardiovascular pharmacotherapy.
- To highlight new drug approvals, label expansions, and key clinical trial outcomes.
Main Methods:
- Comprehensive review of 2025 cardiovascular drug approvals and label expansions.
- Analysis of major randomized clinical trials for cardiovascular drugs.
- Inclusion of data on positive, neutral, and negative trial results.
- Documentation of drug withdrawals due to safety concerns.
Main Results:
- Four new drugs approved: aficamten, etripamil, lerodalcibep, plozasiran.
- Five existing drugs received expanded indications.
- Significant clinical trials yielded both positive and negative results.
- Andexanet-alfa withdrawn from the U.S. market due to safety issues.
Conclusions:
- The year 2025 brought notable progress in cardiovascular pharmacotherapy.
- New agents and expanded uses offer novel treatment avenues.
- Ongoing research into experimental drugs promises future therapeutic options.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
01:29Cardiomyopathy V: Interprofessional Care
661
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
661
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
01:26Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
01:27Coronary Artery Disease V: Interprofessional Care
418
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
418
01:30Heart Failure V: Medical Management
546
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
546